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Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150S134more patients received Plerixafor when a PHPC count was
not performed (45% vs 19%, p ¼ 0.0279). There was no dif-
ference in the number of collections between Cohort 1
(Median¼2, R¼6) and Cohort 2 (Median¼2, R¼4, p¼0.99).
Conclusions: The use a predictive algorithm in deciding on
the timing of use of cytokines and HPC collection can lead to
potentially signiﬁcant savings on material resources and
cost, and improve the efﬁciency of collection.Figure. Mean serial killing of B-cell tumor (CD19pos NALM-6) by CD19-speciﬁc
CAR speciﬁc T cells (n¼3) using single cell serial imaging.184
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Adoptive T-cell immunotherapies are showing increasing
success for the treatment of malignancy. We have previously
demonstrated complete responses to Epstein-Barr Virus (EBV)
-speciﬁc T-cells (EBVSTs) directed against the EBV latent cycle
antigens, LMP1and LMP2 inover 50%of patientswithmultiply
relapsed or refractory EBV+ Hodgkin and non-Hodgkin lym-
phomas (HL and NHL)(1,2).
Unfortunately, themanufacturingproceduresused in this study
pose several impediments to the wider applicability of our
strategy. These include the use of live virus (EBV) and adeno-
viral (Ad) vectors and the difﬁculty of generating EBV-trans-
formed B-cell lines (EBV-LCL) for use as antigen-presenting
cells (APCs) from B-lymphoma patients in the rituxan-era.
To simplify manufacture and make our approach more
broadly applicable, we have replaced EBV antigens expressed
from Ad vectors with overlapping 15mer peptide libraries
(pepmixes) spanning LMP 1/2, as well as EBNA1 and BARF1,
and used pepmix-pulsed dendritic cells for the ﬁrst stimu-
lation followed by pepmix-pulsed, autologus activated T cells
(aATCs) and irradiated costimulatory cells (HLA-negative
K562 cells expressing CD80, CD86, CD83 and 41BB-ligand
[K562-CS] as transgenes) for further expansion.
To date, we have generated 15 EBVSTs from 11 patients (5 HL,
1 NK-T lymphoma, 3 lymphoproliferative diseases, 1 EBV+
diffuse large cell B lymphoma, 1 angioimmunoblastic T cell
lymphoma) enrolled on an IRB and FDA approved clinical
trial NCT01555892. All but one line satisﬁed the eligibility
criteria of the protocol. All EBVSTswere produced in less than
one month compared to 3-6 months with our previous
protocol (mostly due to the EBV-LCL generation). One patient
progressed before the line was ready, but we did not
encounter problems in patients pre-treated with rituxan (5/
11). At the time of cryopreservation EBVSTs were predomi-
nantly central memory (CD45RA-/62L+) (median 80%, range6-93%), while less than 22% (median 12%, range 4-22%) was
effector/effector memory T cells (CD45RA-/62L-). Using a
standard g-INF Elispot, we detected a response to at least 1
antigen in 5/11 patients and against 2 antigens in 2/11 pa-
tients. To date, we have treated 5 patients and while it is too
early to evaluate clinical efﬁcacy, we have detected increases
in the response to the viral antigens in vivo after the infusion.
We will continue to enroll, treat and perform the immuno-
logical follow up to correlate the immunological follow up
results with a clinical response.
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Adoptive cell therapy, based on the adoptive transfer of Tcells
genetically modiﬁed to enforce expression of a chimeric an-
tigen receptor (CAR) has shown considerable promise in
clinical trials, such as with CD19+ malignancies refractory to
conventional treatments. However, efﬁciently predicting
which patientmay beneﬁt from a given CAR design remains a
challenge and undermines the therapeutic potential of such
genetically modiﬁed T cells. Our approach to manufacturing
CD19-speciﬁc T cells is based on electro-transfer of DNA
plasmids from the Sleeping Beauty transposon/transposase
system and selective outgrowth of CAR+ T cells on irradiated
artiﬁcial antigen presenting cells (aAPC). The clinical-grade T
cells prepared for infusion comprise a heterogeneousmixture
and likely only a fraction of the genetically modiﬁed product
contributes to therapeutic efﬁcacy. Thus, we are developing
an approach whereby the therapeutic potential of individual
CAR+ Tcell canbe assessed. Tcells are capable of different anti-
tumor effector functions including cytotoxicity, cytokine
secretion, and homing to target tissues, and currently no
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150 S135methodologies exist that can inform on all of these functions
for a given (single) cell. Therefore, we have implemented an
approach to interrogate the complexity of bulk populations of
manufactured CAR+ T cells, so that the contribution of indi-
vidual cells to theoverall anti-tumoreffect canbe ascertained.
CD19-speciﬁc CAR+ T cells currently being used in clinical
trialswere analyzed at a single cell level using technology that
combines functional screening (cytotoxicity, cytokine pro-
duction)with theirmolecular proﬁles. BulkTcellswhich lysed
tumor targets at 28% (1:1; effector:target ratio) in a standard4
hour chromium lysis assaywereobservedat the single level to
lyse multiple targets and function as serial killers (Figure).
There was no correlation between IFN-g production and
cytolysis. T cells that participated in killing and/or cytokine
secretion were more susceptible to apoptosis than lympho-
cytes that did not participate in effector function. These data
highlight that deconstructing the heterogeneity of a bulk
population into individual cells can be used to determine
whether subsets of T cells can participate in serial killing. The
ability to serially image T-cell killing in massively parallel
arrays will enable investigators to design CAR molecules that
can support multi-hit kill kinetics. This lays the ground work
formore complex studies evaluating cytokine production and
genetic signatures of individual T cells bearing CAR species
that comprise the infusion product.186
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Allogeneic stem cell transplantation (AlloSCT) from HLA-
matched unaffected sibling donors (MSD) has been suc-
cessful for high-risk SCD, but only 14-18% of patients have
such a donor (Freed/Cairo et al, BMT, 2012). Alternate donors
include unrelated adult donors (URD) and umbilical cord
blood (UCB) donors (Cairo et al., BBMT, 2008). URD are
limited and unrelated UCB transplant results are poor (Rad-
hakrishnan K/Cairo et al., BBMT 2013, Kamani et al., BBMT,
2012). In a high-risk FHI TCD thalassemia study, 16/22 cases
engrafted without acute GVHD (aGVHD) and with 90%
overall survival. (Sodani et al., Blood, 2010). FHI TCD AlloSCT,
could expand the donor pool and improve outcomes for SCD.
This SCD consortium trial is investigating the safety, feasi-
bility, EFS, donor chimerism, graft failure, acute and chronic
GVHD, and infectious mortality after FHI TCD AlloSCT in
high-risk SCD patients (Figure 1).
Patients (2-20.99 yrs) without an 8/8 HLA MSD or URD and
who have 1 high-risk SCD feature are eligible. Patients
receive hydroxyurea (60mg/kg/d) and azathioprine (3mg/kg/
d x50d), ﬂudarabine (30mg/m2/d x5d), busulfan (3.2mg/kg/
d x4d), thiotepa (10mg/kg x1d), cyclophosphamide (50mg/kg
x4d), R-ATG (2mg/kg/d x4d), and TLI (500cGy) followed by
FHI T-cell depleted AlloSCT. Acute GVHD prophylaxis is.
